Millions of people enrolled in Medicare Advantage plans stand to pay less each month starting in 2026, with the federal government projecting the average premium will fall to about $14, down from $16.40 this year. The drop comes as the Centers for Medicare and Medicaid Services finalizes a 5.06 percent average payment increase to plans, raising a pointed question: where will that extra money go if not toward cutting premiums even further?
How a 5 percent payment bump produces a $2.40 premium cut
CMS confirmed that the average monthly premium across all Medicare Advantage (MA) plans is expected to fall from $16.40 in 2025 to $14.00 in 2026. At the same time, plans will receive an average payment increase of 5.06 percent year over year. Those two facts sit in tension. A bigger federal payment to insurers does not automatically translate into a bigger premium reduction for enrollees. Instead, plans decide how to allocate the difference between their benchmark payments and their bid costs. Some of that surplus goes to lower premiums. The rest funds supplemental benefits like dental coverage, vision care, hearing aids, or gym memberships.
In counties where 2026 benchmarks land above the national average, insurers have more room to load extra benefits into their packages rather than shave another dollar or two off the monthly charge. That dynamic means the national $14 average will mask wide local variation. A retiree in Miami or Phoenix could see a zero-premium plan with rich extras, while someone in a rural county with a lower benchmark might face a higher premium and fewer add-ons. CMS publishes the underlying benchmark and rate data that plans use to set their bids, but the agency does not release county-level premium distributions that would let consumers see these disparities before open enrollment begins.
The 5.06 percent figure itself reflects several moving parts. CMS’s final payment policy for 2026 adjusts risk scores, star rating bonuses, and county benchmarks in ways that can raise payments for some plans while holding others nearly flat. According to the agency’s payment policy update, the average increase is calculated across all plans and enrollees, smoothing over those differences. That means an individual beneficiary’s plan might see a smaller bump than the headline number, limiting how much room there is to cut premiums or expand extra benefits.
The $2,100 drug cost cap and what it changes for enrollees
Alongside the premium shift, CMS set the out-of-pocket threshold for the Part D catastrophic phase at $2,100 in 2026. That cap, a product of the Inflation Reduction Act’s restructuring of prescription drug benefits, limits what beneficiaries pay before catastrophic coverage kicks in. For people taking expensive specialty medications, the threshold represents a hard ceiling that did not exist a few years ago. Plans must factor this cap into their bids, which can push costs around within the benefit structure even as the headline premium drops.
The interplay between lower premiums and the drug cost cap creates a tradeoff worth watching. Plans absorbing more of the drug spending risk may offset that cost by trimming supplemental benefits or tightening provider networks. CMS has described the overall program outlook as stable, but stability at the national level can coexist with meaningful changes at the plan level. Enrollees who auto-renew without checking their 2026 plan details could miss shifts in formulary coverage or benefit design that affect their actual spending more than a $2.40 monthly premium reduction.
For high-cost drug users, the $2,100 ceiling could outweigh any premium change. Someone who previously faced several thousand dollars in annual out-of-pocket spending might save more from the new cap than from a modest reduction in monthly plan charges. By contrast, healthier enrollees who rarely use prescriptions may notice only the lower premium and small tweaks to ancillary benefits, without feeling the direct impact of the catastrophic threshold.
Gaps in the data and what to track before open enrollment
Several pieces of the picture are still missing. CMS has not published state- or county-level premium breakdowns that would reveal whether certain regions are driving the national average down while others see flat or rising charges. Nor are plan-level benefit packages for 2026 yet available to consumers, leaving open questions about how insurers will balance premiums, cost sharing, and extras in response to the new payment environment.
When plan details are released ahead of open enrollment, beneficiaries and counselors will want to look beyond the average figures. Key items to track include changes in maximum out-of-pocket limits for medical services, shifts in drug tier placement and prior authorization rules, and any reductions in popular supplemental benefits. Network changes, especially in specialist and hospital access, can also serve as a quiet way for plans to manage costs without touching the sticker price of premiums.
Advocates are likely to press CMS for more granular transparency, including clearer summaries of how the 2026 payment changes flow through to consumer-facing costs in different markets. For now, the headline story is that Medicare Advantage premiums are projected to dip even as federal payments climb and a tighter cap on drug spending takes effect. Whether that combination feels like a win to individual enrollees will depend less on the $14 national average than on the specific plan options available in their county when enrollment opens this fall.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
